https://hdl.handle.net/10807/1 2026-07-28T08:59:36Z 2026-07-28T08:59:36Z https://hdl.handle.net/10807/343788 2026-07-28T08:56:56Z 2005-01-01T00:00:00Z

Titolo: BKV infection and hemorrhagic cystitis after allogeneic bone marrow transplant Autori: Fioriti D.; Degener A. M.; Mischitelli M.; Videtta M.; Arancio A.; Sica S.; Sora Federica.; Pietropaolo V. Abstract: Hemorrhagic cystitis (HC) is a well-known complication after allogeneic bone marrow transplant (BMT) and can be related to adenovirus or human polyomavirus BK (BKV) infections. In this study a group of 20 patients after allogeneic BMT has been examined. BMT urine samples were analysed for the presence of Adenovirus and BKV DNA by means of polymerase chain reaction (PCR). 5/20 BMT patients developed HC after BMT. The presence of BKV DNA in urine samples was evident in 3/15 patients without HC and in 5/5 patients with HC. In 2/5 HC-patients the BKV DNA was not found after therapy with Cidofovir and Ribavirin. The search for adenovirus DNA in all samples was negative. The analysis of BKV non-coding control region (NCCR) isolated from urine samples revealed a structure very similar to the archetype in all samples. The RFLP (Restriction Fragment Length Polymorphism assay) showed the presence of BKV subtypes I and IV, with the prevalence of subtype I (4/5). This study supports the hypothesis that HC is mainly related to BKV rather than to adenovirus infection in BMT patients. Moreover, since BKV subtype I was predominant, it is reasonable to hypothesize that a specific BKV subtype could be associated with the development of HC. Copyright © by BIOLIFE, s.a.s.

2005-01-01T00:00:00Z https://hdl.handle.net/10807/343787 2026-07-28T08:54:19Z 2024-01-01T00:00:00Z

Titolo: Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A “Campus CML” Study Autori: Bucelli C.; Capodanno I.; Miggiano M. C.; Cavazzini F.; Crescenzi S.  ; Russo S.; Carmosino I.; Annunziata M.; Sora Federica.; Bonifacio M.; Luciano L.; Caocci G.; Loglisci G.; Elena C.; Lunghi F.; Mullai R.; Attolico I.; Binotto G.; Crisà E.; Sportoletti P.; Di ; Veroli A.; Scortechini A. R.; Leporace A. P.; Maggi A.; Crugnola M.; Stagno F.; Sancetta R.; Murgano P.; Rapezzi D.; Luzi D.; Vincelli D. I.; Galimberti S.; Bocchia M.; Fava C.; Malato A.; Abruzzese E.; Saglio G.; Specchia G.; Breccia M.; Iurlo A.; Tiribelli M.; Latagliata R. Abstract: Objectives: The study aimed to evaluate the utilization of frontline TKI therapy in a large cohort of elderly CP-CML patients. Methods: A retrospective analysis was conducted on 332 CP-CML patients aged 75 years or older among 1929 diagnosed from January 2012 to December 2019 followed at 36 participating Hematology Centers involved in the "Campus CML" project. Results: Among the patients analyzed, 85.8% received imatinib (IM) while 14.2% received second-generation TKIs (2G-TKI), 59.5% dasatinib, and 40.5% nilotinib. Most patients initiated IM at standard dose (67.3%) while 32.7% at reduced dose. A similar trend was observed with 2G-TKIs. The cumulative incidence of permanent TKI discontinuation at 12 months was 28.4%, primarily due to primary resistance (10.1%) and extra-hematologic toxicity (9.5%), with no significant difference between IM and 2G-TKI groups. Following the introduction of generic IM in Italy in 2018, IM usage increased significantly compared with 2G-TKIs. Conclusions: IM was in our Centers the preferred frontline therapy for older CP-CML patients, with increasing utilization after the introduction of generic formulations. However, 2G-TKIs are still used in a substantial proportion of patients, suggesting individualized physician assessments regarding patient suitability and expectations. Further investigation is needed to assess efficacy and safety of reduced TKI doses in this patient population.

2024-01-01T00:00:00Z https://hdl.handle.net/10807/343786 2026-07-28T08:49:17Z 2004-01-01T00:00:00Z

Titolo: Glutamine parenteral supplementation in stem cell transplant (multiple letters) [1] Autori: Piccirillo N.; De Matteis S.; Sora Federica.; Laurenti L.; Chiusolo P.; Leone G.; Sica S.; Pytlik R. Abstract: N/A

2004-01-01T00:00:00Z https://hdl.handle.net/10807/343785 2026-07-28T08:39:38Z 2025-01-01T00:00:00Z

Titolo: Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population Autori: Breccia M.; Rossi A. R.; Giai V.; Martino B.; Fava C.; Annunziata M.; Abruzzese E.; Binotto G.; Barate C.; Nardozza A. P.; Misto A.; Coco P.; Calafiore V.; Carraro M. C.; Cattina F.; Cavazzini F.; Corsetti M. T.; Crucitti L.; Crugnola M.; Di Veroli A.; Ditonno P.; Ermacora A.; Ferrara F.; Genua A.; Gozzini A.; Impera S.; Iurlo A.; Levato L.; Luciano L.; Miggiano M. C.; De Gobbi M.; Santoro M.; Scappini B.; Scortechini A. R.; Patriarca A.; Rosati S.; Russo S.; Sancetta R.; Sanpaolo G.; Santeramo T. M.; Sibilla S.; Sora Federica.; Sportoletti P.; Stagno F.; Trabacchi E.; Castagnetti F. Abstract: Chronic myeloid leukemia (CML) patients who have experienced failure and/or intolerance to multiple lines of treatment have limited therapeutic possibilities. Asciminib is a first-in-class tyrosine kinase inhibitor (TKI) that inhibits the ABL Myristoyl Pocket (STAMP or Specifically Targeting the ABL Myristoyl Pocket) within the BCR::ABL1 oncoprotein. This retrospective Italian analysis reports the efficacy and safety outcomes of asciminib in treating 77 CML patients in chronic phase (CML-CP) within a compassionate use setting. Patients were heavily pretreated with a median of 3 TKIs (55.8% had prior ponatinib exposure). Overall, 57.1% and 42.9% patients switched to asciminib because of resistance and intolerance, respectively. Asciminib maintained or improved molecular responses (MRs) in most patients: as best response, 41 patients (53%) achieved a MR3 or better, with 25 patients (32.5%) reaching deep molecular response (DMR). Greater percentages of intolerant patients achieved MR compared with resistant patients, although the probability of reaching at least a MR3 was not significant between the two groups (p = 0.116). Patients with the T315I mutation responded to asciminib, while ponatinib pre-treated patients showed lower MR improvements compared to naïve patients and had a lower probability to reach a MR3 versus naïve patients (p = 0.0262). These results highlight asciminib remarkable tolerability and efficacy in real-world CML-CP patient population, including heavily pretreated patients, those intolerant and resistant to previous TKIs, and presenting several comorbidities. Trail Registration: The identification code for the MAP is CABL001AIT01M.

2025-01-01T00:00:00Z